Key Insights

Highlights

Success Rate

84% trial completion

Published Results

14 trials with published results (3%)

Research Maturity

103 completed trials (22% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

4.4%

20 terminated out of 458 trials

Success Rate

83.7%

-2.8% vs benchmark

Late-Stage Pipeline

22%

102 trials in Phase 3/4

Results Transparency

14%

14 of 103 completed with results

Key Signals

14 with results84% success20 terminated

Data Visualizations

Phase Distribution

375Total
Not Applicable (45)
Early P 1 (6)
P 1 (54)
P 2 (168)
P 3 (99)
P 4 (3)

Trial Status

Unknown180
Completed103
Recruiting87
Active Not Recruiting34
Not Yet Recruiting28
Terminated20

Trial Success Rate

83.7%

Benchmark: 86.5%

Based on 103 completed trials

Clinical Trials (458)

Showing 20 of 20 trials
NCT07667400Phase 1Not Yet Recruiting

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

NCT06475300Phase 2Recruiting

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT05813626Phase 2Active Not RecruitingPrimary

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

NCT04528394Phase 2CompletedPrimary

Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma

NCT06592599Phase 2RecruitingPrimary

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

NCT03097939Phase 2Active Not RecruitingPrimary

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

NCT06682442Not ApplicableRecruitingPrimary

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

NCT02834013Phase 2Active Not Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT07650266Phase 1Not Yet RecruitingPrimary

A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma

NCT06479811Phase 1Recruiting

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT04825990Phase 2Active Not RecruitingPrimary

Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer

NCT05211232Phase 3Active Not RecruitingPrimary

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

NCT05145660Phase 3Active Not RecruitingPrimary

Optimization of Cervical Nodal CTV for Early and Medium Stage NPC

NCT06277050Phase 3RecruitingPrimary

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

NCT07584499Phase 1Recruiting

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

NCT06852638Phase 2Recruiting

CD70-targeted immunoPET Imaging of Malignant Cancers

NCT04436965Phase 3RecruitingPrimary

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

NCT05780372Phase 3Active Not RecruitingPrimary

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

NCT06197776Recruiting

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

NCT05941741Phase 3RecruitingPrimary

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Scroll to load more

Research Network

Activity Timeline